UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy

MT Newswires Live

2025/06/02

UniQure (QURE) said Monday it has reached alignment with the US Food and Drug Administration on several key elements needed for a biologics license application, or BLA, for AMT-130, its investigational gene therapy for Huntington's disease.

The company said it achieved alignment on the statistical analysis plan and Chemistry, Manufacturing, and Controls information to support the BLA submission planned for Q1 2026.

UniQure plans to request for priority review designation along with its BLA submission, it added. AMT-130 has been granted FDA's regenerative medicine advanced therapy and breakthrough therapy designations.

Shares of UniQure were up about 3.8% in recent trading Monday.

Price: 15.02, Change: +0.55, Percent Change: +3.77

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540926791"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540926791\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540926791?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540926791","market":"sh","top_or_hot":-1,"title":"UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy","media":"MT Newswires Live","content":"<html><body><p> UniQure (QURE) said Monday it has reached alignment with the US Food and Drug Administration on several key elements needed for a biologics license application, or BLA, for AMT-130, its investigational gene therapy for Huntington's disease.</p><p>The company said it achieved alignment on the statistical analysis plan and Chemistry, Manufacturing, and Controls information to support the BLA submission planned for Q1 2026.</p><p>UniQure plans to request for priority review designation along with its BLA submission, it added. AMT-130 has been granted FDA's regenerative medicine advanced therapy and breakthrough therapy designations.</p><p>Shares of UniQure were up about 3.8% in recent trading Monday.</p><p>Price: 15.02, Change: +0.55, Percent Change: +3.77</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUniQure Reaches Alignment With FDA on Potential Huntington's Disease Gene Therapy\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-02 23:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> UniQure (QURE) said Monday it has reached alignment with the US Food and Drug Administration on several key elements needed for a biologics license application, or BLA, for AMT-130, its investigational gene therapy for Huntington's disease.</p><p>The company said it achieved alignment on the statistical analysis plan and Chemistry, Manufacturing, and Controls information to support the BLA submission planned for Q1 2026.</p><p>UniQure plans to request for priority review designation along with its BLA submission, it added. AMT-130 has been granted FDA's regenerative medicine advanced therapy and breakthrough therapy designations.</p><p>Shares of UniQure were up about 3.8% in recent trading Monday.</p><p>Price: 15.02, Change: +0.55, Percent Change: +3.77</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540926791","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540926791","pubTimestamp":1748876806,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"UniQure (QURE) said Monday it has reached alignment with the US Food and Drug Administration on several key elements needed for a biologics license application, or BLA, for AMT-130, its investigationa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","QURE":"uniQure N.V."},"translate_title":"UniQure与FDA就潜在的亨廷顿舞蹈症基因疗法达成一致","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QURE":0.9},"content_text":"UniQure (QURE) said Monday it has reached alignment with the US Food and Drug Administration on several key elements needed for a biologics license application, or BLA, for AMT-130, its investigational gene therapy for Huntington's disease.The company said it achieved alignment on the statistical analysis plan and Chemistry, Manufacturing, and Controls information to support the BLA submission planned for Q1 2026.UniQure plans to request for priority review designation along with its BLA submission, it added. AMT-130 has been granted FDA's regenerative medicine advanced therapy and breakthrough therapy designations.Shares of UniQure were up about 3.8% in recent trading Monday.Price: 15.02, Change: +0.55, Percent Change: +3.77","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}